Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion type Assertion NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_head.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion description "[Blockade of either CXCL5 or CXCR2 may be a critical adjunct antiangiogenic therapy against pancreatic cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_provenance.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion evidence source_evidence_literature NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_provenance.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion SIO_000772 21356384 NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_provenance.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion wasDerivedFrom befree-20150227 NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_provenance.
- NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_assertion wasGeneratedBy ECO_0000203 NP502759.RASzGMTpYMYp53lUgyN76kU-QyukiCSk4UeBNoPhgiwSg130_provenance.